Valrox Readout Could Ignite M&A Interest in BioMarin
Mindgram
April 11, 20202 min
A positive readout on Valrox, the late-stage hemophilia A therapy being developed by Biomarin Pharmaceutical, could have a significant impact on potential M&A opportunities for the company. Valrox is on track to be approved as the first gene therapy…read more
contact@capitolscience.com
©2020 Mindgram Technologies, LLC